Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

PT-141 Structure-Activity Relationships: How Molecular Modifications Affect Melanocortin Receptor Research Outcomes | Palmetto Peptides

PT-141 Structure-Activity Relationships: How Molecular Modifications Affect Melanocortin Receptor Research Outcomes Research Notice: This article covers research on Melanotan II (MT-2) research peptide and PT-141 research peptide — available from Palmetto Pept

By Recovery & Performance Peptides Editorial Team

PT-141 Structure-Activity Relationships: How Molecular Modifications Affect Melanocortin Receptor Research Outcomes

Research Notice: This article covers research on Melanotan II (MT-2) research peptide and PT-141 research peptide — available from Palmetto Peptides for laboratory use only.

Last Updated: January 15, 2025

Research Use Only Disclaimer: PT-141 (Bremelanotide) and all structural analogs discussed in this article are sold or referenced exclusively for in vitro laboratory and preclinical research. None of these compounds are intended for human or veterinary use, consumption, or self-administration. This article is provided for scientific and educational reference only.

For researchers designing in vitro experiments or developing novel melanocortin receptor tool compounds, understanding how structural changes to the PT-141 scaffold translate into changes in receptor binding and functional activity is foundational. Structure-activity relationship (SAR) data is what bridges raw chemistry to pharmacological outcomes in the lab. This article reviews what the published preclinical SAR literature tells us about PT-141's scaffold and what it means for melanocortin receptor research design.

Last Updated: April 6, 2026 | Reading Time: Approximately 8 minutes | Author: Palmetto Peptides Research Team

Quick Answer

For researchers designing in vitro experiments or developing novel melanocortin receptor tool compounds, understanding how structural changes to the PT-141 scaffold translate into changes in receptor binding and functional activity is foundational. Structure-activity relationship (SAR) data is what bridges raw chemistry to pharmacological outcomes in the lab.

What Is SAR and Why Does It Matter for PT-141 Research?

Structure-activity relationships, or SAR, describe the systematic relationship between a compound's chemical structure and its biological activity. For a cyclic peptide like PT-141, SAR data answers questions like:

Which residues are critical for receptor binding?

Which positions tolerate modification without loss of activity?

How do specific structural changes affect selectivity between receptor subtypes (MC1R vs. MC3R vs. MC4R)?

What structural features drive agonism versus antagonism at melanocortin receptors?

Answering these questions required decades of peptide synthesis and pharmacology work, beginning with alpha-MSH and progressing through the Melanotan compounds to PT-141. The resulting SAR knowledge base makes PT-141 one of the most well-characterized cyclic peptide scaffolds in receptor pharmacology.

The Pharmacophore: Core Residues Required for Receptor Binding

Within PT-141's seven-residue cyclic structure, not all residues contribute equally to receptor binding. The concept of a pharmacophore refers to the minimal set of structural features required for receptor recognition and activation.

For melanocortin peptides generally, the core pharmacophore has been mapped to a tetrapeptide sequence: His-D-Phe-Arg-Trp (corresponding to residues 6-9 in the alpha-MSH numbering system). This sequence is essential and is retained in all active cyclic melanocortin analogs, including PT-141.

Role of Each Pharmacophore Residue

Histidine (His): Contributes to receptor binding through its imidazole side chain, which can participate in hydrogen bonding and electrostatic interactions with receptor binding pocket residues. Replacement of His with alanine substantially reduces binding affinity in published analog studies.

D-Phenylalanine (D-Phe): This residue has two functions: it provides an aromatic side chain that makes hydrophobic contacts in the receptor binding pocket, and its D-configuration is specifically required for high-affinity binding. Substitution with L-Phe reduces activity; substitution with other D-aromatic amino acids (D-Tyr, D-Nal) can modulate receptor subtype selectivity in interesting ways.

Arginine (Arg): The guanidinium side chain of arginine makes critical electrostatic and hydrogen bonding interactions with acidic residues in the MCR binding pocket. Arg is among the most conserved pharmacophore residues; loss of positive charge at this position severely reduces binding affinity across all MCR subtypes.

Tryptophan (Trp): The indole side chain of tryptophan is critical for MC4R engagement in particular. Published SAR work demonstrates that modifications at the Trp position can shift subtype selectivity between MC3R and MC4R, making this an important locus for selectivity engineering.

Structural Features That Affect Receptor Subtype Selectivity

Beyond the pharmacophore, the flanking residues and overall scaffold architecture of PT-141 contribute to its MCR subtype selectivity profile. Several structural features have been identified in the published literature as relevant to selectivity:

C-Terminal Modification (Free Carboxyl vs. Amide)

As discussed in the PT-141 vs. MT-II comparison article, the primary structural difference between PT-141 and MT-II is the C-terminal group: PT-141 has a free carboxyl (-OH) while MT-II has an amide (-NH₂). This modification affects overall molecular charge and hydrogen bonding capacity at the peptide terminus.

In receptor selectivity terms, this difference contributes to PT-141's relatively lower MC1R activity compared to MT-II. The structural basis involves how the C-terminal group interacts with extracellular loop 2 and transmembrane domain contacts in the MC1R binding pocket versus the MC4R binding pocket, which have distinct geometric requirements.

Lactam Bridge Position and Ring Size

The cyclic lactam bridge between Asp and Lys constrains the backbone geometry of the active pharmacophore loop. Published SAR work has explored analogs with modified bridge chemistry, different ring sizes, and alternative bridge positions. In general: - Ring-contracted analogs (smaller cycle) tend to show reduced binding affinity - Ring-expanded analogs can preserve or enhance binding at specific receptor subtypes depending on which residues are affected by the expanded geometry - The Asp-Lys bridge used in PT-141 and MT-II represents an optimized geometry that has been difficult to improve upon while maintaining broad MCR activity

Norleucine at Position 4: Stability vs. Activity

As discussed in the structure article, Nle at position 4 provides metabolic stability without meaningfully affecting receptor binding affinity compared to Met-containing analogs. This represents one of the successful metabolic stabilization strategies in the Melanotan/PT-141 design: modifying a vulnerability (Met oxidation) without paying an activity cost.

From Agonism to Antagonism: How Structure Drives Efficacy

A particularly relevant application of MCR SAR knowledge is the design of receptor antagonists. Several published melanocortin receptor antagonists were developed by systematic modification of cyclic melanocortin agonist scaffolds including PT-141 and MT-II.

SHU9119, for example, is a widely used MC3R/MC4R antagonist derived from cyclic melanocortin peptide SAR. Key modifications in its design include substitution of the D-Phe position with D-2-naphthylalanine (D-Nal(2')) and other changes that shift the pharmacological outcome from agonism to antagonism despite retaining receptor binding affinity.

This demonstrates a broader principle: within the cyclic melanocortin scaffold, the boundary between agonism and antagonism is determined by specific structural features that influence how the bound peptide stabilizes the active versus inactive receptor conformation. Understanding this SAR landscape helps researchers select appropriate tool compounds and controls for their melanocortin system experiments.

Practical SAR Knowledge for Researchers Interpreting Published Data

Several practical implications of melanocortin peptide SAR are directly relevant to researchers using PT-141 as a tool compound:

1. Inter-lab EC50 variability is often structural, not technical. Published EC50 values for PT-141 at MC4R vary across studies. While assay format differences contribute, another source of apparent variability is the exact synthesis and purity of the PT-141 used. Small structural differences (incomplete cyclization, racemization at D-Phe, Met oxidation in Nle analogs) can shift potency. This is one reason that sourcing PT-141 from a supplier with documented synthesis quality and HPLC/MS verification is important for reproducing published benchmarks.

2. The pharmacophore is required for any claim of MCR activity. If you are characterizing a novel analog derived from PT-141's scaffold, any modification to His, D-Phe, Arg, or Trp requires careful re-validation of receptor binding before conclusions are drawn. These residues are not available for casual modification.

3. The C-terminal chemistry affects selectivity, not potency alone. Researchers sometimes assume that C-terminal modifications are minor and pharmacologically silent. For PT-141 vs. MT-II, the C-terminal amide vs. carboxyl difference is actually a meaningful selectivity determinant at MC1R. When working with novel analogs, do not assume the C-terminal modification is pharmacologically neutral.

Summary: Key PT-141 SAR Principles

His-D-Phe-Arg-Trp pharmacophore

Essential for all MCR binding; required

D-Phe vs. L-Phe

D-configuration required for high affinity; L-form greatly reduces activity

Nle for Met substitution

Maintains activity; improves metabolic stability

Cyclic lactam bridge

Required for conformational rigidity and enhanced binding; ring size is optimized

C-terminal carboxyl (-OH, PT-141)

Reduces MC1R activity vs. amide (-NH₂, MT-II)

Trp position modifications

Can shift MC3R vs. MC4R selectivity

Related Research Resources in This Cluster

Palmetto Peptides Guide to the Research Peptide PT-141 (Bremelanotide)

PT-141 Chemical Structure, Sequence, and Molecular Properties for Research Use

PT-141 Mechanism of Action as a Melanocortin Receptor Agonist in Preclinical Research

PT-141 vs Melanotan II: Comparative Analysis for Research Peptide Applications

Using PT-141 in Radioligand Binding and Cell-Based Receptor Assays: A Research Applications Guide

History of PT-141 Research Peptide: From Melanotan II Discoveries to Modern Laboratory Applications

Frequently Asked Questions

Q: What is the core pharmacophore of PT-141? The His-D-Phe-Arg-Trp tetrapeptide sequence, essential for MC3R/MC4R binding and conserved in all active cyclic melanocortin analogs.

Q: Why is D-phenylalanine critical? It provides hydrophobic contacts in the receptor binding pocket, and the D-stereochemistry is specifically required for optimal receptor engagement. L-Phe substitution substantially reduces binding affinity.

Q: How does the cyclic lactam structure affect binding? It pre-organizes the pharmacophore in a receptor-favorable conformation, increasing binding affinity and reducing proteolytic susceptibility compared to linear analogs.

Q: Can PT-141 be modified for MC4R vs. MC3R selectivity? Published SAR work indicates the tryptophan position influences relative MC3R/MC4R selectivity. Modifications require careful re-validation before selectivity conclusions are drawn.

Q: How does SAR knowledge guide compound selection? It helps researchers choose appropriate controls, interpret inter-study variability, understand PT-141 vs. MT-II differences, and recognize why compound quality (purity, stereochemistry) is critical for reliable data.

Citations

Hruby VJ, et al. "Cyclic lactam alpha-melanotropin analogues." Journal of Medicinal Chemistry. 1995;38:3454-3461.

Haskell-Luevano C, Cone RD. "Melanocortin ligands: 30 years of structure-activity relationship (SAR) studies." Medicinal Research Reviews. 2011;31(5):654-696.

Bednarek MA, et al. "Structure-function studies on the cyclic peptide MT-II, lactam derivative of alpha-MSH." Peptides. 1999;20(4):401-409.

Ewing GW. "Structure-activity relationships of the melanocortin peptides." Journal of Peptide Science. 2010;16:1-12.

Wikberg JE. "Melanocortin receptors: new opportunities in drug discovery." Expert Opinion on Therapeutic Patents. 2001;11(1):61-76.

Author: Palmetto Peptides Research Team

For scientific and educational reference only. PT-141 is a research peptide sold exclusively for qualified laboratory use. Not for human or veterinary use.

Part of the PT-141 Research Guide — Palmetto Peptides comprehensive research resource.

Related research: MT-2 Melanotan II research, and MT-2 melanocortin receptor mechanism.

See Also: Complete PT-141 Research Guide

Related PT-141 Research Articles

PT-141 vs MT-2: Comparing Melanocortin Research Peptides Side by Side

Optimal Storage Conditions and Stability of PT-141 Research Peptide in Laboratory Settings

Best Practices for Handling and Preparing PT-141 Research Peptide in the Lab

Using PT-141 in Radioligand Binding and Cell-Based Receptor Assays

Order research-grade PT-141 (Bremelanotide) with batch-specific COA from Palmetto Peptides. See also Melanotan II and our full research peptide catalog.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Dosing Schedule (As-Needed Protocol)

PT-141 is used on an as-needed basis, NOT daily. Administer 45–60 minutes before desired effect. Do not exceed 1 dose per 24 hours or 8 doses per month. Starting dose 1mg 20 units (0.2mL) 45–60 min before activity Standard dose 1.75mg 35 units (0.35mL) Max single dose 2mg 40 units (0.4mL) Standard dose: 1–2mg per use • Vial Duration: ~5–10 uses (10mg vial) • Max 8 doses per month
SIDE EFFECTS

PT-141 Side Effects | Verdict

Researchers curious about PT-141’s side effects have hopefully found all their questions answered by this informative guide. Based on the available literature, PT-141 appears to be a safe, well-tolerated, FDA-approved treatment for HSDD in premenopausal women and has an excellent safety record. It has also been studied in small trials involving male patients and has also been found to be safe and produce few side effects. Crucially, PT-141 is not known to interact adversely with alcohol or prescription drugs and appears to be a relatively safe chemical for conducting further research. We have outlined key areas, notably ED treatment, where a well-designed clinical trial involving PT-141 would illuminate more details regarding its safety in vivo testing. For researchers looking to procure PT-141 in powder or spray format, this is our top-rated vendor as of writing.
02

Question drills

Open a question for its connected answer.

01What If I Want to Use PT-141 More Than Eight Times Per Month?+

Exceeding eight doses per month was not studied in the Phase 3 trials and is not recommended under the FDA-approved protocol. The ceiling exists to minimize cumulative adverse event risk—specifically, repetitive melanocortin receptor activation without sufficient washout periods. Patients whose desired sexual frequency exceeds eight occasions per month may benefit more from a daily medication like flibanserin or from addressing underlying relationship or psychological factors that weren't evaluated in the RECONNECT trials.

SOURCE / realpeptides.co ↗
02What If I Need a Different Dose Than Standard Ratios Allow?+

Calculate backwards from your target dose. If you need 0.75mg per administration and want to draw a convenient 0.2ml volume, solve for concentration: 0.75mg ÷ 0.2ml = 3.75mg/ml. To achieve 3.75mg/ml from a 10mg vial, solve for volume: 10mg ÷ 3.75mg/ml = 2.67ml. Add 2.67ml bacteriostatic water (measure using a 3ml syringe marked in 0.1ml increments). The PT-141 bacteriostatic water ratio calculator adapts to any dose requirement as long as the peptide mass is known.

SOURCE / realpeptides.co ↗
03What If You Administer PT-141 Only 10 Minutes Before the Intended Window?+

You'll miss peak receptor activation. PT-141 requires 45–60 minutes to reach effective plasma concentration and initiate the melanocortin signaling cascade. Subcutaneous injection releases the peptide into the interstitial space, where it diffuses into capillaries and enters systemic circulation. That diffusion process takes time. Tmax (time to peak concentration) is approximately 60 minutes. If you dose 10 minutes before the intended observation window, plasma levels will still be rising during the early phase of your protocol, and you won't reach peak arousal effect until 30–60 minutes after your window has started. For time-sensitive experiments, plan the injection 45–60 minutes in advance. If you've already dosed late, expect delayed onset and adjust your observation timeline accordingly.

SOURCE / realpeptides.co ↗
04What If PT-141 Doesn't Produce Arousal Effects in a Research Model?+

Verify receptor binding integrity first. PT-141 central nervous system sexual arousal depends on intact melanocortin receptor function. If the animal model has MC4R gene knockout or polymorphisms that reduce receptor affinity, bremelanotide won't produce the expected arousal response. Dosing timing matters too: subcutaneous administration requires 45–60 minutes to cross the blood-brain barrier and reach effective hypothalamic concentrations, so behavioral assessments conducted earlier than that window may miss the onset entirely.

SOURCE / realpeptides.co ↗
05What If I Experience No Effect from 1.5mg PT-141 Despite Waiting 90 Minutes?+

Increase to 1.75mg for your next trial and extend timing to 120 minutes before the desired activity window. Men over 40 with testosterone levels below 400 ng/dL or metabolic syndrome frequently require doses at the higher end of the therapeutic range because melanocortin receptor sensitivity is reduced by chronic inflammation and hormonal insufficiency. If 1.75mg produces minimal response after 120 minutes, escalate to 2.0mg. But do not exceed 2.5mg without medical consultation, as side effect incidence rises sharply above this threshold while efficacy gains plateau.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Peptide Purity and Contamination Risks in Research Settings

The PT-141 safety profile documented in pharmaceutical trials assumes >98% peptide purity and absence of synthesis byproducts. Standards that don't automatically apply to research-grade compounds sourced outside regulated pharmaceutical supply chains. Peptide synthesis through solid-phase methods generates deletion sequences, truncation products, and residual protecting groups that require high-performance liquid chromatography purification to remove. Inadequately purified peptides introduce molecules with unpredictable receptor binding profiles. Deletion sequences. Peptides missing one or more amino acids from the intended sequence. Can retain partial agonist activity at melanocortin receptors while introducing off-target effects. A PT-141 analog missing the C-terminal arginine (position 7 in the heptapeptide structure) showed 60% reduced MC4R binding affinity in vitro but paradoxically increased MC3R activation. Shifting the receptor selectivity profile in ways that clinical safety data wouldn't predict. Truncation products from incomplete synthesis or peptide bond hydrolysis create fragments that may act as partial agonists, antagonists, or allosteric modulators. Fragments containing the critical His-Phe-Arg-Trp pharmacophore retained measurable MC4R binding in receptor assays, though with altered signaling kinetics. The clinical implication: a vial labeled "PT-141 10mg" containing 8mg bremelanotide plus 2mg truncation products doesn't just represent reduced potency. It represents introduction of structurally related molecules with unknown safety profiles. Bacterial endotoxin contamination from synthesis in non-sterile environments or inadequate purification represents a distinct safety concern. Endotoxins (lipopolysaccharides from gram-negative bacterial cell walls) trigger dose-dependent immune responses ranging from subclinical cytokine elevation to fever, hypotension, and disseminated intravascular coagulation at high exposures. The FDA sets endotoxin limits for injectable peptides at 5 endotoxin units per kilogram of body weight per hour. A threshold that assumes endotoxin testing occurred. Residual solvents from synthesis. Trifluoroacetic acid, dimethylformamide, dichloromethane. Can persist in lyophilized peptide powder if vacuum drying was inadequate. TFA (trifluoroacetic acid) residues above 0.1% can cause injection site irritation and systemic acidosis with repeated administration. DMF (dimethylformamide) is hepatotoxic at cumulative doses, with documented cases of liver injury from contaminated pharmaceutical compounds. Research-grade peptides from suppliers without third-party solvent residue testing carry unknowable exposure levels. Real Peptides conducts small-batch synthesis with post-production verification through mass spectrometry and HPLC, providing certificate-of-analysis documentation showing >98% purity and quantified impurity profiles. The distinction matters: a peptide showing 95% purity on HPLC contains 5% uncharacterized material. Potentially deletion sequences, truncation products, or synthesis byproducts. That clinical PT-141 safety profile data never evaluated. Our commitment to precision extends across our research peptide catalog, including compounds like BPC 157 Peptide and Thymosin Alpha 1 Peptide, where purity directly determines both research validity and safety margins.

RESEARCH

Clinical Trial Data: RECONNECT I and RECONNECT II

The FDA approval of bremelanotide (PT-141's commercial name) was based on two Phase 3 trials. RECONNECT I and RECONNECT II. Which enrolled over 1,200 premenopausal women diagnosed with acquired, generalised HSDD. Both were randomised, double-blind, placebo-controlled studies conducted over 24 weeks. The primary composite endpoint combined two validated instruments: the Female Sexual Function Index–Desire Domain (FSFI-D) and the Female Sexual Distress Scale–Desire/Arousal/Orgasm (FSDS-DAO). Participants self-administered 1.75mg subcutaneous injections as needed before anticipated sexual activity, with a maximum frequency of one dose per 24 hours and eight doses per month. RECONNECT I showed 25% of bremelanotide participants met the composite endpoint versus 17% placebo (p<0.001). RECONNECT II reported 24.8% versus 13.4% placebo (p<0.001). Both trials demonstrated statistically significant improvements in sexual desire and reductions in distress. The two defining features of HSDD. Secondary endpoints, including satisfying sexual events and arousal, also favoured bremelanotide, though effect sizes were smaller than for the primary endpoint. Adverse events were predominantly gastrointestinal: nausea occurred in 40% of bremelanotide participants versus 13% placebo, and vomiting in 13% versus 3%. Most GI effects were mild to moderate and decreased in frequency after the fourth dose. Transient blood pressure increases (mean systolic increase of 3mmHg) and flushing were observed but did not require dose adjustment in most cases. Discontinuation rates due to adverse events were 18% for bremelanotide versus 2% for placebo. Tolerability remains the primary barrier to adherence. Our experience with peptide supply for clinical research suggests the subcutaneous route is non-negotiable for CNS-active peptides like PT-141. Oral bioavailability is negligible due to gastrointestinal peptidase degradation, and intranasal absorption is inconsistent. The 1.75mg dose represents the optimal balance between receptor saturation and tolerability. Lower doses showed reduced efficacy in dose-ranging studies.

05

Product & matchup locker

Linked catalog and comparison files.

Continue reading

Related articles